Novocure Operating Margin from 2010 to 2025
| NVCR Stock | USD 18.77 1.01 5.11% |
Check Novocure financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novocure's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.2 M, Interest Expense of 18.2 M or Selling General Administrative of 97.7 M, as well as many indicators such as Price To Sales Ratio of 5.04, Dividend Yield of 0.0 or PTB Ratio of 13.33. Novocure financial statements analysis is a perfect complement when working with Novocure Valuation or Volatility modules.
Novocure | Operating Margin |
Latest Novocure's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Novocure over the last few years. It is Novocure's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novocure's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.39) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Novocure Operating Margin Regression Statistics
| Arithmetic Mean | (2.26) | |
| Coefficient Of Variation | (120.77) | |
| Mean Deviation | 2.45 | |
| Median | (0.30) | |
| Standard Deviation | 2.73 | |
| Sample Variance | 7.47 | |
| Range | 6.2655 | |
| R-Value | 0.87 | |
| Mean Square Error | 1.94 | |
| R-Squared | 0.76 | |
| Significance | 0.000012 | |
| Slope | 0.50 | |
| Total Sum of Squares | 112.03 |
Novocure Operating Margin History
About Novocure Financial Statements
Novocure shareholders use historical fundamental indicators, such as Operating Margin, to determine how well the company is positioned to perform in the future. Although Novocure investors may analyze each financial statement separately, they are all interrelated. The changes in Novocure's assets and liabilities, for example, are also reflected in the revenues and expenses on on Novocure's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. NovoCure operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 1167 people.
Additional Tools for Novocure Stock Analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.